References

Akiyama, K., Hora, M., Tatemichi, S., Masuda, N., Nakamura, S., Yamagishi, R. et al. (1999). KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther 291, 81-91.

Banerjee, P.P., Banerjee, S., and Brown, T.R. (2001). Increased androgen receptor expression correlates with development of age-dependent, lobe-specific spontaneous hyperplasia of the brown Norway rat prostate. Endocrinology 142, 4066-4075.

Banerjee, P.P., Banerjee, S., Lai, J.M., Strandberg, J.D., Zirkin, B.R., and Brown, T.R. (1998). Age-dependent and lobe-specific spontaneous hyperplasia in the brown Norway rat prostate. Biol Reprod 59, 1163-1170.

Bayne, C.W., Donnelly, F., Chapman, K., Bollina, P., Buck, C., and Habib, F. (1998). A novel coculture model for benign prostatic hyperplasia expressing both isoforms of 5 alpha-reductase. J Clin Endocrinol Metab 83, 206-213.

Berry, S.J., Coffey, D.S., Walsh, P.C., and Ewing, L.R. (1984). The development of human benign prostatic hyperplasia with age. J Urol 132, 474-479.

Celec, P. and Starka, L. (2003). Dehydroepiandrosterone—Is the fountain of youth drying out? Physiol Res 52, 397-407.

Cordon-Cardo, C., Koff, A., Drobnjak, M., Capodieci, P., Osman, I., Millard, S.S. et al. (1998). Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 90, 1284-1291.

Dillner, K., Kindblom, J., Flores-Morales, A., Pang, S.T., Tornell, J., Wennbo, H. et al. (2002). Molecular characterization of prostate hyperplasia in prolactin-transgenic mice by using cDNA representational difference analysis. Prostate 52, 139-149.

Dillner, K., Kindblom, J., Flores-Morales, A., Shao, R., Tornell, J., Norstedt, G. et al. (2003). Gene expression analysis of prostate hyperplasia in mice overexpressing the prolactin gene specifically in the prostate. Endocrinology 144, 4955-4966.

Fujimoto, N., Suzuki, T., Honda, H., and Kitamura, S. (2004). Estrogen enhancement of androgen-responsive gene expression in hormone-induced hyperplasia in the ventral prostate of F344 rats. Cancer Sci 95, 711-715.

Girman, C.J. (1998). Natural history and epidemiology of benign prostatic hyperplasia: relationship among urologic measures. Urology 51, 8-12.

Golomb, E., Kruglikova, A., Dvir, D., Parnes, N., and Abramovici, A. (1998). Induction of atypical prostatic hyperplasia in rats by sympathomimetic stimulation. Prostate 34, 214-221.

Guo, Q.L., Ding, Q.L., and Wu, Z.Q. (2004). Effect of baicalein on experimental prostatic hyperplasia in rats and mice. Biol Pharm Bull 27, 333-337.

Habib, F.K., Ross, M., and Bayne, C.W. (2000). Development of a new in vitro model for the study of benign prostatic hyperplasia. Prostate Suppl 9, 15-20.

Ito, K., Fukabori, Y., Shibata, Y., Suzuki, K., Mieda, M., Gotanda, K. et al. (2000). Effects of a new steroidal aromatase inhibitor, TZA-2237, and/or chlormadinone acetate on hormone-induced and spontaneous canine benign prostatic hyperplasia. Eur J Endocrinol 143, 543-554.

Kindblom, J., Dillner, K., Sahlin, L., Robertson, F., Ormandy, C., Tornell, J. et al. (2003). Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology 144, 2269-2278.

Lepor, H. (2005). Pathophysiology of benign prostatic hyperplasia in the aging male population. Rev Urol 7, S3-S12.

Levi, F., Lucchini, F., Negri, E., Boyle, P., and La Vecchia, C. (2003). Recent trends in mortality from benign prostatic hyperplasia. Prostate 56, 207-211.

Mahapokai, W., Van Sluijs, F.J., and Schalken, J.A. (2000). Models for studying benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 3, 28-33.

Marinese, D., Patel, R., and Walden, P.D. (2003). Mechanistic investigation of the adrenergic induction of ventral prostate hyperplasia in mice. Prostate 54, 230-237.

Mitra, S.K., Sundaram, R., Mohan, A.R., Gopumadhavan, S., Venkataranganna, M.V., Venkatesha, U. et al. (1999). Protective effect of Prostane in experimental prostatic hyperplasia in rats. Asian J Androl 1, 175-179.

Oesterling, J.E., Jacobsen, S.J., Chute, C.G., Guess, H.A., Girman, C.J., Panser, L.A. et al. (1993). Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270, 860-864.

Olbina, G., Miljkovic, D., Hoffman, R.M., and Geller, J. (1998). New sensitive discovery histoculture model for growth-inhibition studies in prostate cancer and BPH. Prostate 37, 126-129.

Parnes, H.L., Thompson, I.M., and Ford, L.G. (2005). Prevention of hormone-related cancers: Prostate cancer. J Clin Oncol 23, 368-377.

Prakash, K., Pirozzi, G., Elashoff, M., Munger, W., Waga, I., Dhir, R. et al. (2002). Symptomatic and asymptomatic benign prostatic hyperplasia: Molecular differentiation by using microarrays. Proc Natl Acad Sci USA 99, 7598-7603.

Risbridger, G.P., Bianco, J.J., Ellem, S.J., and McPherson, S.J. (2003). Oestrogens and prostate cancer. Endocr Relat Cancer 10, 187-191.

Roberts, R.O., Jacobson, D.J., Rhodes, T., Klee, G.G., Leiber, M.M., and Jacobsen, S.J. (2004). Serum sex hormones and measures of benign prostatic hyperplasia. Prostate 61, 124-131.

Schulman, C. and Lunenfeld, B. (2002). The ageing male. World J Urol 20, 4-10.

Skolarikos, A., Thorpe, A.C., and Neal, D.E. (2004). Lower urinary tract symptoms and benign prostatic hyper-plasia. Minerva Urol Nefrol 56, 109-122.

Steiner, M.S., Couch, R.C., Raghow, S., and Stauffer, D. (1999). The chimpanzee as a model of human benign prostatic hyperplasia. J Urol 162, 1454-1461.

Takao, T., Tsujimura, A., Coetzee, S., Salm, S.N., Lepor, H., Shapiro, E. et al. (2003). Stromal/epithelial interactions of murine prostatic cell lines in vivo: a model for benign prostatic hyperplasia and the effect of doxazosin on tissue size. Prostate 54, 17-24.

Thorpe, A. and Neal, D. (2003). Benign prostatic hyperplasia. Lancet 361, 1359-1367.

Van Coppenolle, F., Le Bourhis, X., Carpentier, F., Delaby, G., Cousse, H., Raynaud, J.P. et al. (2000). Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyper-prolactinemia: Comparison with finasteride. Prostate 4I3, 49-58.

vom Saal, F.S., Timms, B.G., Montano, M.M., Palanza, P., Thayer, K.A., Nagel, S.C. et al. (1997). Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc Natl Acad Sci USA 94, 2056-2061.

Yokota, T., Honda, K., Tsuruya, Y., Nomiya, M., Yamaguchi, O., Gotanda, K. et al. (2004). Functional and anatomical effects of hormonally induced experimental prostate growth: A urodynamic model of benign prostatic hyperplasia (BPH) in the beagle. Prostate 58, 156-163.

Zaviacic, M. and Ablin, R.J. (1998). The female prostate. J Natl Cancer Inst 90, 713-714.

Zaviacic, M. and Ablin, R.J. (2000). The female prostate and prostate-specific antigen. Immunohistochemical localization, implications of this prostate marker in women and reasons for using the term "prostate" in the human female. Histol Histopathol 15, 131-142.

Zhang, X., Na, Y., and Guo, Y. (2004). Biologic feature of prostatic hyperplasia developed in spontaneously hypertensive rats. Urology 63, 983-988.

This page intentionally left blank

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment